サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1555496

セファロスポリン薬市場：世代別、タイプ別、剤形別、適応症別、流通チャネル別、地域別 - 産業分析、市場規模、市場シェア、2024年～2032年の予測

Cephalosporin Drug Market, By Generation, By Type, By Formulation, By Indication, By Distribution Channel, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

出版日
ページ情報
英文 269 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.91円
セファロスポリン薬市場：世代別、タイプ別、剤形別、適応症別、流通チャネル別、地域別 - 産業分析、市場規模、市場シェア、2024年～2032年の予測
出版日: 2024年08月04日
発行: AnalystView Market Insights
ページ情報: 英文 269 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポートハイライト

セファロスポリン薬の市場規模は2023年に195億4,220万米ドルとなり、2024年から2032年にかけてCAGR 3.10％で拡大

セファロスポリン薬市場-市場力学

ヘルスケアのためのインフラ整備の高まり

セファロスポリン薬市場は、製薬企業による新薬製剤への取り組みや、緊急時の医療インフラへの投資増加により拡大しています。また、経済成長国のヘルスケア施設の整備は、より質の高い医療インフラを生み出します。細菌性疾患の罹患率の上昇により、効率的な治療薬に対するニーズが高まっており、細菌性治療薬の創薬分野の進歩に拍車をかけています。セファロスポリン薬の市場は、特に発展途上国におけるヘルスケア施設建設への官民セクターの投資拡大や、細菌性疾患に関する啓発キャンペーンの高まりにより拡大しています。

セファロスポリン薬市場-主要インサイト

当社のリサーチアナリストの分析によると、世界市場は予測期間（2024-2032年）に約3.10%のCAGRで毎年成長すると予測されています。

世代セグメンテーションに基づくと、第2世代セファロスポリンカテゴリは2023年に最大市場シェアを示すと予測されました。

タイプ別セグメントでは、ブランドセファロスポリン薬カテゴリーが2023年に主要セグメントとなった。

剤形別では、経口薬が2023年の主要セグメントでした。

適応症別では、皮膚感染症が2023年の主要セグメントでした。

流通チャネル別では、2023年に病院薬局カテゴリーが主要セグメントでした。

地域別では、北米が2023年の主要収益源であった

セファロスポリン薬市場-セグメンテーション分析：

世界のセファロスポリン薬市場は、世代、タイプ、製剤、適応症、流通チャネル、地域に基づいてセグメント化されます。

市場は世代に基づいて以下のカテゴリーに分けられる：第一世代セファロスポリン、第二世代セファロスポリン、第三世代セファロスポリン、第四世代セファロスポリン、第五世代セファロスポリン第二世代セファロスポリンのカテゴリーが市場を独占しています。セファロスポリンファミリーは第2世代セファロスポリンのイントロダクションよって進化的変化を遂げており、これは第1世代前駆体に代わるβラクタム抗生物質のサブクラスです。セフォキシチン、セフロキシム、セファクロル、セフプロジルなどがその例です。これらの抗生物質は作用範囲が広く、様々なグラム陽性菌やグラム陰性菌によく効く。臨床的に汎用性の高い第2世代セファロスポリンは、皮膚疾患、中耳炎、尿路感染症、呼吸器感染症などに広く使用されています。特にグラム陰性菌に対するカバー率が高いです。

市場は剤形によって以下のカテゴリーに分けられる：経口剤｛錠剤、カプセル剤、液剤｝と注射剤です。経口剤が市場を独占しており、予測期間中もその優位性は維持されるであろう。経口セファロスポリンと呼ばれる抗生物質のクラスは、経口使用を目的とし、様々な細菌感染を治療する実用的な手段を提供します。経口セファロスポリン系抗生物質は、細菌の細胞壁の形成を阻害することにより、細菌の増殖と拡散を抑制します。この特定のクラスの抗生物質は、広範囲の細菌に対して有効であるため、皮膚、軟部組織、尿路、呼吸器系に影響を及ぼす感染症に頻繁に使用されます。各患者に特有の細菌性疾患とそのニーズに基づいて、特定の経口セファロスポリンが、推奨される投与量と治療期間とともに選択されます。

セファロスポリン薬市場-地理的洞察

地理的に、この市場は北米、ラテンアメリカ、欧州、アジア太平洋、中東およびアフリカの地域に広がっています。これらの地域は、ビジネスを展開する国によってさらに分けられます。

予測期間中、北米がセファロスポリン薬の世界市場で最大のシェアを占めると予想されています。強力なヘルスケアシステムとR&Dの重視が北米産業を定義しています。最新のセファロスポリン薬は、様々な状況における細菌感染の頻度により、依然として高い需要があります。協力的なコラボレーションと独創的な製品開発により、定評ある製薬会社が市場を巧みに操っています。この地域は、厳格な規制基準によって証明されるように、医薬品の安全性と有効性に全力を注いでいます。抗生物質耐性との闘いは継続的な技術革新を促すため、強力なセファロスポリン製剤が開発されています。さらに、これらの薬剤を感染管理計画に組み込むことは、多額のヘルスケア支出によって促進されており、合弁事業によって研究開発および流通の能力が向上しています。

さらに、セファロスポリン製剤市場は、アジア太平洋地域の予測期間中、世界で最も速い速度で拡大すると予想されています。この地域における感染症の高い流行が、セファロスポリン薬の需要を牽引しています。市場競争とイノベーションを促進する市場力学には、既存企業や新興企業が幅広く含まれています。入手しやすさや価格設定などの経済的要因は、医薬品の入手可能性に大きく影響します。ヘルスケア部門の政策は、セファロスポリン薬へのアクセスを改善し、インフラを強化するための努力を積極的に先導しています。アジアは医療ツーリズムの主要な目的地であり、セファロスポリン製剤のような高級医薬品への需要を高め、製薬業界が世界ヘルスケア基準を遵守していることを浮き彫りにしています。

セファロスポリン薬市場-競合情勢：

市場は異質な情勢を特徴としており、複数の新規プレーヤーの参入が予想されることから、競争激化が予想されます。同市場では、Merck &Co.Ltd.、Pfizer Inc.、Allergan plc.、GlaxoSmithKline plc.、Abbott Laboratories、Sanofi S.A.などの大手企業は、効率性、完全性、安全性を重視しながら、競争力を維持するために継続的に技術を改善しています。競合他社を凌駕するために、これらの企業は提携、製品革新、合弁事業などの戦略的イニシアティブに高い優先順位を置いています。セファロスポリン薬の市場シェアを大幅に拡大することが、彼らの主な目標です。

目次

第1章 セファロスポリン薬市場概要

  • 調査範囲
  • 市場推定年

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 セファロスポリン薬の主要市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 セファロスポリン薬産業研究

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長見通しマッピング
  • 規制枠組み分析

第5章 セファロスポリン薬市場： COVID-19の影響分析

  • COVID-19以前の影響分析
  • COVID-19後の影響分析

第6章 セファロスポリン薬市場情勢

  • セファロスポリン薬市場シェア分析、2023年
  • 主要メーカー別内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 セファロスポリン薬市場- 世代別

  • 概要
    • 世代別セグメントシェア分析
    • 第1世代セファロスポリン
    • 第2世代セファロスポリン
    • 第3世代セファロスポリン
    • 第4世代セファロスポリン
    • 第5世代セファロスポリン

第8章 セファロスポリン薬市場- タイプ別

  • 概要
    • タイプ別セグメントシェア分析
    • ブランドセファロスポリン薬
    • ジェネリックセファロスポリン薬

第9章 セファロスポリン薬市場- 剤形別

  • 概要
    • 剤形別セグメントシェア分析
    • 経口
      • 錠剤
      • カプセル
      • 液体
    • 注射

第10章 セファロスポリン薬市場- 適応症別

  • 概要
    • 適応症別セグメントシェア分析
    • 呼吸器感染症
    • 皮膚感染症
    • 耳の感染症
    • 細菌感染
    • 尿路感染症
    • 性感染症
    • 副鼻腔感染症
    • 外科的予防
    • その他
      • 髄膜炎
      • 急性腹部感染症
      • 骨盤感染症

第11章 セファロスポリン薬市場- 流通チャネル別

  • 概要
    • 流通チャネル別セグメントシェア分析
    • 病院薬局
    • 小売薬局
    • オンライン薬局

第12章 セファロスポリン薬市場- 地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋（APAC）
    • 概要
    • アジア太平洋地域の主要メーカー
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東およびアフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第13章 主要ベンダー分析- セファロスポリン薬業界

  • 競合ダッシュボード
  • 企業プロファイル
    • Merck &Co. Inc.
    • Pfizer Inc.
    • Lupin Limited
    • Teva Pharmaceutical Industries Ltd.
    • F. Hoffmann-La Roche AG
    • Allergan plc.
    • Abbott Laboratories
    • GlaxoSmithKline plc.
    • Basilea Pharmaceutica Ltd.
    • Sanofi SA
    • B. Braun Melsungen AG.
    • Others

第14章 アナリストの全方位展望

目次
Product Code: ANV3567

REPORT HIGHLIGHT

Cephalosporin Drug Market size was valued at USD 19,542.2 Million in 2023, expanding at a CAGR of 3.10% from 2024 to 2032.

The broad class of antibiotics known as cephalosporins is a subclass of beta-lactams. Many bacterial infections are treated with cephalosporin, a broad-spectrum bactericidal antibiotic. There are branded and generic forms of cephalosporin drugs. For various indications, different generations of cephalosporins are chosen and used. The most widely prescribed broad-spectrum antibiotics, which can be used in a range of therapeutic settings, are third-generation products. Among the third-generation cephalosporins, cefotaxime and ceftizoxime exhibit the highest gram-positive bactericidal activity. The market is growing because of the increasing occurrence of infectious diseases, which is fueling the need for preventative and effective pharmacological treatments. The market for cephalosporin drugs is expanding due to an increase in bacterial illnesses, such as staph infections, pneumonia, sinusitis, strep throat, tonsillitis, and others.

Cephalosporin Drug Market- Market Dynamics

Rising Infrastructure Improvements for Healthcare

The market for cephalosporin drugs is expanding due to efforts by pharmaceutical companies to produce new drug formulations and an increase in investments made in healthcare infrastructure for emergency purposes. Furthermore, higher-quality medical infrastructure is produced when healthcare facilities in economically growing nations are upgraded. The need for efficient treatment medications has grown due to the rising incidence of bacterial illnesses, which is fueling advances in the field of drug discovery for bacterial treatment medications. The market for cephalosporin drugs is expanding due to growing public and private sector investments in the construction of healthcare facilities, particularly in developing nations, and a growing awareness campaign on bacterial illnesses.

Cephalosporin Drug Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 3.10% over the forecast period (2024-2032)

Based on generation segmentation, the second-generation cephalosporin category was predicted to show maximum market share in the year 2023

Based on type segmentation, the branded cephalosporin drugs category was the leading segment in 2023

Based on formulation segmentation, the oral category was the leading segment in 2023

Based on indication segmentation, the skin infection category was the leading segment in 2023

Based on distribution channel segmentation, the hospital pharmacies category was the leading segment in 2023

On the basis of region, North America was the leading revenue generator in 2023

Cephalosporin Drug Market- Segmentation Analysis:

The Global Cephalosporin Drug Market is segmented on the basis of Generation, Type, Formulation, Indication, Distribution Channel, and Region.

The market is divided into the following categories based on generation: First-generation Cephalosporin, Second-generation Cephalosporin, Third-generation Cephalosporin, Fourth-generation Cephalosporin, and Fifth-generation Cephalosporin The second-generation cephalosporin category dominates the market. The cephalosporin family has undergone evolutionary change with the introduction of second-generation cephalosporins, which are a subclass of beta-lactam antibiotics that replace their first-generation precursors. Products like cefoxitin, cefuroxime, cefaclor, and cefprozil exemplify these advancements. The culprit for having a wider range of action, these antibiotics work well against a variety of Gram-positive and Gram-negative bacteria. Clinically versatile second-generation cephalosporins are widely used for skin problems, otitis media, urinary tract infections, and respiratory tract infections. They provide increased coverage, particularly against Gram-negative organisms.

The market is divided into the following categories based on formulation: Oral {Tablets, Capsules, and Liquid} and Injection. The oral category dominates the market and is likely to maintain its dominance during the forecast period. A class of antibiotics called oral cephalosporins is intended for oral use and provides a practical means of treating various bacterial infections. Oral cephalosporins work by preventing the formation of bacterial cell walls, which inhibits the growth and spread of bacteria. This particular class of antibiotics is frequently used for infections affecting the skin, soft tissues, urinary tract, and respiratory system because of its effectiveness against a wide range of bacteria. Based on the unique bacterial illness and the needs of each patient, a specific oral cephalosporin is chosen, along with the recommended dosage and length of treatment.

Cephalosporin Drug Market- Geographical Insights

Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.

Over the course of the forecast period, North America is anticipated to hold the greatest share of the global market for cephalosporin drugs. Strong healthcare systems and an emphasis on R&D have defined the North American industry. Modern cephalosporin drugs are still in high demand due to the frequency of bacterial infections in a variety of contexts. By means of cooperative collaborations and inventive product creation, well-established pharmaceutical companies adeptly maneuver the market. The area is committed to drug safety and efficacy, as evidenced by strict regulatory standards. Since combating antibiotic resistance encourages ongoing innovation, powerful cephalosporin formulations have been developed. Furthermore, the incorporation of these medications into infection control plans is facilitated by significant healthcare spending, and joint ventures improve the capacity for research, development, and distribution.

In addition, the cephalosporin drug market is anticipated to expand at the fastest rate in the world during the projected period in Asia Pacific. The high prevalence of infectious infections in the area is driving the demand for cephalosporin drugs. A wide range of existing and rising firms are included in the market dynamics, which promote competition and innovation. Economic factors, including accessibility and pricing greatly influence the availability of drugs. Policies in the healthcare sector are aggressively spearheading efforts to improve access to cephalosporin drugs and strengthen infrastructure. Asia is a leading destination for medical tourism, which drives up demand for premium pharmaceuticals, such as cephalosporin drugs, and highlights the pharmaceutical industry's adherence to global healthcare standards.

Cephalosporin Drug Market- Competitive Landscape:

The market is characterized by a heterogeneous landscape, and the anticipated influx of multiple new players is likely to intensify competitiveness. Well-established leaders in the market, such as Merck & Co. Inc., Pfizer Inc., Allergan plc., GlaxoSmithKline plc., Abbott Laboratories, and Sanofi S.A., emphasize efficiency, integrity, and safety while continuously improving their technologies to keep a competitive edge. To outperform their competitors, these organizations place a high priority on strategic initiatives, including alliances, product innovations, and joint ventures. Gaining a substantial market share for cephalosporin drugs is their main goal.

Recent Developments:

April 2024: The U.S. Food and Drug Administration (FDA) approved Zevtera (ceftobiprole medocaril sodium injection) by Basilea Pharmaceutical International Ltd. to treat severe bacterial infections in adults and pediatric patients.

April 2024: The US Food and Drug Administration (USFDA) approved the sale of the 25 mg extended-release Mirabegron tablets in the US market for the pharmaceutical business Lupin, based in Mumbai. The extended-release Mirabegron tablets are used to treat bladder issues, such as an overactive bladder.

March 2023: Hikma Pharmaceuticals PLC (Hikma) introduced Cefazolin injection to treat bacterial infections of the bone, skin, blood, genitalia, and joints, among other parts of the body. It is projected that this product launch will propel market expansion.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CEPHALOSPORIN DRUG MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Merck & Co. Inc.
  • Pfizer Inc.
  • Lupin Limited
  • Teva Pharmaceutical Industries Ltd.
  • F. Hoffmann-La Roche AG
  • Allergan plc.
  • Abbott Laboratories
  • GlaxoSmithKline plc.
  • Basilea Pharmaceutica Ltd.
  • Sanofi S.A.
  • B. Braun Melsungen AG.
  • Others

GLOBAL CEPHALOSPORIN DRUG MARKET, BY GENERATION- MARKET ANALYSIS, 2019 - 2032

  • First-generation Cephalosporin
  • Second-generation Cephalosporin
  • Third-generation Cephalosporin
  • Fourth-generation Cephalosporin
  • Fifth-generation Cephalosporin

GLOBAL CEPHALOSPORIN DRUG MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

  • Branded Cephalosporin Drugs
  • Generic Cephalosporin Drugs

GLOBAL CEPHALOSPORIN DRUG MARKET, BY FORMULATION- MARKET ANALYSIS, 2019 - 2032

  • Oral
  • Tablets
  • Capsules
  • Liquid
  • Injection

GLOBAL CEPHALOSPORIN DRUG MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

  • Respiratory Tract Infection
  • Skin Infection
  • Ear Infection
  • Bacterial Infection
  • Urinary Tract Infection
  • Sexually Transmitted Infection
  • Sinus Infection
  • Surgical Prophylaxis
  • Others
  • Meningitis
  • Acute Abdomen Infection
  • Pelvic infection

GLOBAL CEPHALOSPORIN DRUG MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

GLOBAL CEPHALOSPORIN DRUG MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Cephalosporin Drug Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Cephalosporin Drug Market Snippet by Generation
    • 2.1.2. Cephalosporin Drug Market Snippet by Type
    • 2.1.3. Cephalosporin Drug Market Snippet by Formulation
    • 2.1.4. Cephalosporin Drug Market Snippet by Indication
    • 2.1.5. Cephalosporin Drug Market Snippet by Distribution Channel
    • 2.1.6. Cephalosporin Drug Market Snippet by Country
    • 2.1.7. Cephalosporin Drug Market Snippet by Region
  • 2.2. Competitive Insights

3. Cephalosporin Drug Key Market Trends

  • 3.1. Cephalosporin Drug Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Cephalosporin Drug Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Cephalosporin Drug Market Opportunities
  • 3.4. Cephalosporin Drug Market Future Trends

4. Cephalosporin Drug Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Cephalosporin Drug Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Cephalosporin Drug Market Landscape

  • 6.1. Cephalosporin Drug Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Cephalosporin Drug Market - By Generation

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Generation, 2023 & 2032 (%)
    • 7.1.2. First-generation Cephalosporin
    • 7.1.3. Second-generation Cephalosporin
    • 7.1.4. Third-generation Cephalosporin
    • 7.1.5. Fourth-generation Cephalosporin
    • 7.1.6. Fifth-generation Cephalosporin

8. Cephalosporin Drug Market - By Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Type, 2023 & 2032 (%)
    • 8.1.2. Branded Cephalosporin Drugs
    • 8.1.3. Generic Cephalosporin Drugs

9. Cephalosporin Drug Market - By Formulation

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Formulation, 2023 & 2032 (%)
    • 9.1.2. Oral
      • 9.1.2.1. Tablets
      • 9.1.2.2. Capsules
      • 9.1.2.3. Liquid
    • 9.1.3. Injection

10. Cephalosporin Drug Market - By Indication

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Indication, 2023 & 2032 (%)
    • 10.1.2. Respiratory Tract Infection
    • 10.1.3. Skin Infection
    • 10.1.4. Ear Infection
    • 10.1.5. Bacterial Infection
    • 10.1.6. Urinary Tract Infection
    • 10.1.7. Sexually Transmitted Infection
    • 10.1.8. Sinus Infection
    • 10.1.9. Surgical Prophylaxis
    • 10.1.10. Others
      • 10.1.10.1. Meningitis
      • 10.1.10.2. Acute Abdomen Infection
      • 10.1.10.3. Pelvic infection

11. Cephalosporin Drug Market - By Distribution Channel

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
    • 11.1.2. Hospital Pharmacies
    • 11.1.3. Retail Pharmacies
    • 11.1.4. Online Pharmacies

12. Cephalosporin Drug Market- By Geography

  • 12.1. Introduction
    • 12.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 12.2. North America
    • 12.2.1. Overview
    • 12.2.2. Cephalosporin Drug Key Manufacturers in North America
    • 12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.2.4. North America Market Size and Forecast, By Generation, 2019 - 2032 (US$ Million)
    • 12.2.5. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 12.2.6. North America Market Size and Forecast, By Formulation, 2019 - 2032 (US$ Million)
    • 12.2.7. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 12.2.8. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.2.9. U.S.
      • 12.2.9.1. Overview
      • 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.9.3. U.S. Market Size and Forecast, By Generation, 2019 - 2032 (US$ Million)
      • 12.2.9.4. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.2.9.5. U.S. Market Size and Forecast, By Formulation, 2019 - 2032 (US$ Million)
      • 12.2.9.6. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.2.9.7. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.2.10. Canada
      • 12.2.10.1. Overview
      • 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.10.3. Canada Market Size and Forecast, By Generation, 2019 - 2032 (US$ Million)
      • 12.2.10.4. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.2.10.5. Canada Market Size and Forecast, By Formulation, 2019 - 2032 (US$ Million)
      • 12.2.10.6. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.2.10.7. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.3. Europe
    • 12.3.1. Overview
    • 12.3.2. Cephalosporin Drug Key Manufacturers in Europe
    • 12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.3.4. Europe Market Size and Forecast, By Generation, 2019 - 2032 (US$ Million)
    • 12.3.5. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 12.3.6. Europe Market Size and Forecast, By Formulation, 2019 - 2032 (US$ Million)
    • 12.3.7. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 12.3.8. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.9. Germany
      • 12.3.9.1. Overview
      • 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.9.3. Germany Market Size and Forecast, By Generation, 2019 - 2032 (US$ Million)
      • 12.3.9.4. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.9.5. Germany Market Size and Forecast, By Formulation, 2019 - 2032 (US$ Million)
      • 12.3.9.6. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.9.7. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.10. Italy
      • 12.3.10.1. Overview
      • 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.10.3. Italy Market Size and Forecast, By Generation, 2019 - 2032 (US$ Million)
      • 12.3.10.4. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.10.5. Italy Market Size and Forecast, By Formulation, 2019 - 2032 (US$ Million)
      • 12.3.10.6. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.10.7. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.11. United Kingdom
      • 12.3.11.1. Overview
      • 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.11.3. United Kingdom Market Size and Forecast, By Generation, 2019 - 2032 (US$ Million)
      • 12.3.11.4. United Kingdom Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.11.5. United Kingdom Market Size and Forecast, By Formulation, 2019 - 2032 (US$ Million)
      • 12.3.11.6. United Kingdom Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.11.7. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.12. France
      • 12.3.12.1. Overview
      • 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.12.3. France Market Size and Forecast, By Generation, 2019 - 2032 (US$ Million)
      • 12.3.12.4. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.12.5. France Market Size and Forecast, By Formulation, 2019 - 2032 (US$ Million)
      • 12.3.12.6. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.12.7. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.13. Russia
      • 12.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.13.2. Russia Market Size and Forecast, By Generation, 2019 - 2032 (US$ Million)
      • 12.3.13.3. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.13.4. Russia Market Size and Forecast, By Formulation, 2019 - 2032 (US$ Million)
      • 12.3.13.5. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.13.6. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.14. Netherlands
      • 12.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.14.2. Netherlands Market Size and Forecast, By Generation, 2019 - 2032 (US$ Million)
      • 12.3.14.3. Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.14.4. Netherlands Market Size and Forecast, By Formulation, 2019 - 2032 (US$ Million)
      • 12.3.14.5. Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.14.6. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.15. Sweden
      • 12.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.15.2. Sweden Market Size and Forecast, By Generation, 2019 - 2032 (US$ Million)
      • 12.3.15.3. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.15.4. Sweden Market Size and Forecast, By Formulation, 2019 - 2032 (US$ Million)
      • 12.3.15.5. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.15.6. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.16. Poland
      • 12.3.16.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.16.2. Poland Market Size and Forecast, By Generation, 2019 - 2032 (US$ Million)
      • 12.3.16.3. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.16.4. Poland Market Size and Forecast, By Formulation, 2019 - 2032 (US$ Million)
      • 12.3.16.5. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.16.6. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.17. Rest of Europe
      • 12.3.17.1. Overview
      • 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.17.3. Rest of the Europe Market Size and Forecast, By Generation, 2019 - 2032 (US$ Million)
      • 12.3.17.4. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.17.5. Rest of the Europe Market Size and Forecast, By Formulation, 2019 - 2032 (US$ Million)
      • 12.3.17.6. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.17.7. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.4. Asia Pacific (APAC)
    • 12.4.1. Overview
    • 12.4.2. Cephalosporin Drug Key Manufacturers in Asia Pacific
    • 12.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.4.4. Asia Pacific Market Size and Forecast, By Generation, 2019 - 2032 (US$ Million)
    • 12.4.5. Asia Pacific Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 12.4.6. Asia Pacific Market Size and Forecast, By Formulation, 2019 - 2032 (US$ Million)
    • 12.4.7. Asia Pacific Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 12.4.8. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.9. India
      • 12.4.9.1. Overview
      • 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.9.3. India Market Size and Forecast, By Generation, 2019 - 2032 (US$ Million)
      • 12.4.9.4. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.9.5. India Market Size and Forecast, By Formulation, 2019 - 2032 (US$ Million)
      • 12.4.9.6. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.9.7. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.10. China
      • 12.4.10.1. Overview
      • 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.10.3. China Market Size and Forecast, By Generation, 2019 - 2032 (US$ Million)
      • 12.4.10.4. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.10.5. China Market Size and Forecast, By Formulation, 2019 - 2032 (US$ Million)
      • 12.4.10.6. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.10.7. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.11. Japan
      • 12.4.11.1. Overview
      • 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.11.3. Japan Market Size and Forecast, By Generation, 2019 - 2032 (US$ Million)
      • 12.4.11.4. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.11.5. Japan Market Size and Forecast, By Formulation, 2019 - 2032 (US$ Million)
      • 12.4.11.6. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.11.7. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.12. South Korea
      • 12.4.12.1. Overview
      • 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.12.3. South Korea Market Size and Forecast, By Generation, 2019 - 2032 (US$ Million)
      • 12.4.12.4. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.12.5. South Korea Market Size and Forecast, By Formulation, 2019 - 2032 (US$ Million)
      • 12.4.12.6. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.12.7. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.13. Australia
      • 12.4.13.1. Overview
      • 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.13.3. Australia Market Size and Forecast, By Generation, 2019 - 2032 (US$ Million)
      • 12.4.13.4. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.13.5. Australia Market Size and Forecast, By Formulation, 2019 - 2032 (US$ Million)
      • 12.4.13.6. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.13.7. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.14. Thailand
      • 12.4.14.1. Overview
      • 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.14.3. Thailand Market Size and Forecast, By Generation, 2019 - 2032 (US$ Million)
      • 12.4.14.4. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.14.5. Thailand Market Size and Forecast, By Formulation, 2019 - 2032 (US$ Million)
      • 12.4.14.6. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.14.7. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.15. Indonesia
      • 12.4.15.1. Overview
      • 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.15.3. Indonesia Market Size and Forecast, By Generation, 2019 - 2032 (US$ Million)
      • 12.4.15.4. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.15.5. Indonesia Market Size and Forecast, By Formulation, 2019 - 2032 (US$ Million)
      • 12.4.15.6. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.15.7. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.16. Philippines
      • 12.4.16.1. Overview
      • 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.16.3. Philippines Market Size and Forecast, By Generation, 2019 - 2032 (US$ Million)
      • 12.4.16.4. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.16.5. Philippines Market Size and Forecast, By Formulation, 2019 - 2032 (US$ Million)
      • 12.4.16.6. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.16.7. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.17. Rest of APAC
      • 12.4.17.1. Overview
      • 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.17.3. Rest of APAC Market Size and Forecast, By Generation, 2019 - 2032 (US$ Million)
      • 12.4.17.4. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.17.5. Rest of APAC Market Size and Forecast, By Formulation, 2019 - 2032 (US$ Million)
      • 12.4.17.6. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.17.7. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.5. Latin America
    • 12.5.1. Overview
    • 12.5.2. Cephalosporin Drug Key Manufacturers in Latin America
    • 12.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.5.4. Latin America Market Size and Forecast, By Generation, 2019 - 2032 (US$ Million)
    • 12.5.5. Latin America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 12.5.6. Latin America Market Size and Forecast, By Formulation, 2019 - 2032 (US$ Million)
    • 12.5.7. Latin America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 12.5.8. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.9. Brazil
      • 12.5.9.1. Overview
      • 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.9.3. Brazil Market Size and Forecast, By Generation, 2019 - 2032 (US$ Million)
      • 12.5.9.4. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.5.9.5. Brazil Market Size and Forecast, By Formulation, 2019 - 2032 (US$ Million)
      • 12.5.9.6. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.5.9.7. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.10. Mexico
      • 12.5.10.1. Overview
      • 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.10.3. Mexico Market Size and Forecast, By Generation, 2019 - 2032 (US$ Million)
      • 12.5.10.4. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.5.10.5. Mexico Market Size and Forecast, By Formulation, 2019 - 2032 (US$ Million)
      • 12.5.10.6. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.5.10.7. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.11. Argentina
      • 12.5.11.1. Overview
      • 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.11.3. Argentina Market Size and Forecast, By Generation, 2019 - 2032 (US$ Million)
      • 12.5.11.4. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.5.11.5. Argentina Market Size and Forecast, By Formulation, 2019 - 2032 (US$ Million)
      • 12.5.11.6. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.5.11.7. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.12. Colombia
      • 12.5.12.1. Overview
      • 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.12.3. Colombia Market Size and Forecast, By Generation, 2019 - 2032 (US$ Million)
      • 12.5.12.4. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.5.12.5. Colombia Market Size and Forecast, By Formulation, 2019 - 2032 (US$ Million)
      • 12.5.12.6. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.5.12.7. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.13. Rest of LATAM
      • 12.5.13.1. Overview
      • 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.13.3. Rest of LATAM Market Size and Forecast, By Generation, 2019 - 2032 (US$ Million)
      • 12.5.13.4. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.5.13.5. Rest of LATAM Market Size and Forecast, By Formulation, 2019 - 2032 (US$ Million)
      • 12.5.13.6. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.5.13.7. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.6. Middle East and Africa
    • 12.6.1. Overview
    • 12.6.2. Cephalosporin Drug Key Manufacturers in Middle East and Africa
    • 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.6.4. Middle East and Africa Market Size and Forecast, By Generation, 2019 - 2032 (US$ Million)
    • 12.6.5. Middle East and Africa Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 12.6.6. Middle East and Africa Market Size and Forecast, By Formulation, 2019 - 2032 (US$ Million)
    • 12.6.7. Middle East and Africa Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 12.6.8. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.9. Saudi Arabia
      • 12.6.9.1. Overview
      • 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.9.3. Saudi Arabia Market Size and Forecast, By Generation, 2019 - 2032 (US$ Million)
      • 12.6.9.4. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.6.9.5. Saudi Arabia Market Size and Forecast, By Formulation, 2019 - 2032 (US$ Million)
      • 12.6.9.6. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.6.9.7. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.10. United Arab Emirates
      • 12.6.10.1. Overview
      • 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.10.3. United Arab Emirates Market Size and Forecast, By Generation, 2019 - 2032 (US$ Million)
      • 12.6.10.4. United Arab Emirates Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.6.10.5. United Arab Emirates Market Size and Forecast, By Formulation, 2019 - 2032 (US$ Million)
      • 12.6.10.6. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.6.10.7. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.11. Israel
      • 12.6.11.1. Overview
      • 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.11.3. Israel Market Size and Forecast, By Generation, 2019 - 2032 (US$ Million)
      • 12.6.11.4. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.6.11.5. Israel Market Size and Forecast, By Formulation, 2019 - 2032 (US$ Million)
      • 12.6.11.6. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.6.11.7. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.12. Turkey
      • 12.6.12.1. Overview
      • 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.12.3. Turkey Market Size and Forecast, By Generation, 2019 - 2032 (US$ Million)
      • 12.6.12.4. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.6.12.5. Turkey Market Size and Forecast, By Formulation, 2019 - 2032 (US$ Million)
      • 12.6.12.6. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.6.12.7. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.13. Algeria
      • 12.6.13.1. Overview
      • 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.13.3. Algeria Market Size and Forecast, By Generation, 2019 - 2032 (US$ Million)
      • 12.6.13.4. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.6.13.5. Algeria Market Size and Forecast, By Formulation, 2019 - 2032 (US$ Million)
      • 12.6.13.6. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.6.13.7. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.14. Egypt
      • 12.6.14.1. Overview
      • 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.14.3. Egypt Market Size and Forecast, By Generation, 2019 - 2032 (US$ Million)
      • 12.6.14.4. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.6.14.5. Egypt Market Size and Forecast, By Formulation, 2019 - 2032 (US$ Million)
      • 12.6.14.6. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.6.14.7. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.15. Rest of MEA
      • 12.6.15.1. Overview
      • 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.15.3. Rest of MEA Market Size and Forecast, By Generation, 2019 - 2032 (US$ Million)
      • 12.6.15.4. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.6.15.5. Rest of MEA Market Size and Forecast, By Formulation, 2019 - 2032 (US$ Million)
      • 12.6.15.6. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.6.15.7. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

13. Key Vendor Analysis- Cephalosporin Drug Industry

  • 13.1. Competitive Dashboard
  • 13.2. Company Profiles
    • 13.2.1. Merck & Co. Inc.
    • 13.2.2. Pfizer Inc.
    • 13.2.3. Lupin Limited
    • 13.2.4. Teva Pharmaceutical Industries Ltd.
    • 13.2.5. F. Hoffmann-La Roche AG
    • 13.2.6. Allergan plc.
    • 13.2.7. Abbott Laboratories
    • 13.2.8. GlaxoSmithKline plc.
    • 13.2.9. Basilea Pharmaceutica Ltd.
    • 13.2.10. Sanofi S.A.
    • 13.2.11. B. Braun Melsungen AG.
    • 13.2.12. Others

14. 360 Degree Analyst View

15. Appendix

  • 15.1. Research Methodology
  • 15.2. References
  • 15.3. Abbreviations
  • 15.4. Disclaimer
  • 15.5. Contact Us